DAVENPORT & Co LLC reduced its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 7.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,132,092 shares of the company's stock after selling 163,477 shares during the quarter. DAVENPORT & Co LLC owned approximately 0.08% of Sanofi worth $118,433,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in SNY. Cardinal Capital Management raised its holdings in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after acquiring an additional 199 shares in the last quarter. Gradient Investments LLC raised its holdings in shares of Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after acquiring an additional 200 shares in the last quarter. Providence Capital Advisors LLC boosted its position in Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after acquiring an additional 201 shares in the last quarter. Perigon Wealth Management LLC boosted its position in Sanofi by 3.1% during the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after acquiring an additional 201 shares in the last quarter. Finally, Bailard Inc. boosted its position in Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after acquiring an additional 220 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.
Sanofi Stock Performance
SNY stock traded up $0.16 during midday trading on Wednesday, reaching $49.21. The stock had a trading volume of 669,787 shares, compared to its average volume of 2,336,851. The stock has a market cap of $120.69 billion, a PE ratio of 17.58, a P/E/G ratio of 0.99 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The firm has a fifty day simple moving average of $50.84 and a two-hundred day simple moving average of $52.05. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the business posted $1.78 EPS. The firm's quarterly revenue was down 11.0% on a year-over-year basis. As a group, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a $2.0369 dividend. This represents a yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio is 57.14%.
Analyst Ratings Changes
Several analysts have issued reports on SNY shares. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $61.50.
Check Out Our Latest Research Report on Sanofi
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
